Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

Patients Receiving Every Four-Week Subcutaneous Golimumab Also Experienced

Improvements in Physical Function and Disease Activity

PARIS, June 11 /PRNewswire/ -- Findings from two new Phase 3 studies showed that patients receiving every four-week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg and weekly methotrexate (MTX) experienced significant improvements in the signs and symptoms of rheumatoid arthritis (RA) as well as in physical function and disease activity, with some patients achieving remission as measured by Disease Activity Score (DAS28). Findings from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies showed the efficacy of golimumab in two important populations - MTX-naive patients and patients with active RA despite ongoing treatment with MTX. These data were presented at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology. Golimumab is currently in the most comprehensive initial Phase 3 development program to date for an anti-tumor necrosis factor (TNF)-alpha biologic therapy with ongoing studies for the treatment of RA, psoriatic arthritis and ankylosing spondylitis.

In the study, GOlimumab FOR subjects With Active RA Despite MTX (GO-FORWARD), both the 50 mg and 100 mg doses of golimumab were studied in patients whose disease was active despite ongoing treatment with MTX. At week 14, 55 percent of patients receiving golimumab 50 mg plus MTX and 56 percent receiving golimumab 100 mg plus MTX achieved at least 20 percent improvement in signs and symptoms of RA (ACR 20), compared to 33 percent of patients receiving placebo and MTX (p<0.01 and p<0.001, respectively). Improvements were seen as early as first clinical assessment, which was four weeks after the first golimumab injection, and generally continued to improve over time.

"The data in this study demonstrate that golimumab is beneficial in improving numerous disease parameters, including in
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 As health officials across the Midwest warn against ... in Michigan will offer free diagnostic ... Meijer pharmacists to administer tests and, in some cases, fill ... participating in the study. The Grand ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), ... that the United States Patent and Trademark Office has ... patent application directed to the fundamental technology involved in ... delivery systems. The allowable subject matter is directed to ...
... Aug. 3, 2011 Reportlinker.com announces ... is available in its catalogue: ... and Services Market 2011-2021 - what ... http://www.reportlinker.com/p0578544/Lyophilisation-for-Pharmaceuticals-Technology-and-Services-Market-2011-2021---what-are-the-revenue-prospects.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ...
Cached Medicine Technology:Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology 2Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology 3Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 2Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 3Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 5Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 6Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 7Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 8Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 9Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 10Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 11Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 12Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 13
(Date:4/18/2014)... have made a discovery that turns 160 years of ... material long known to be essential for the fast ... is not as ubiquitous as thought, according to a ... Harvard Stem Cell Institute (HSCI) and the University,s Department ... Professor Jeff Lichtman, of Harvard,s Department of Molecular and ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2
... badly treated fractures are some of the reasons why ... often laid up, according to orthopaedic experts here. ... with many delicate and complicated surgeries being performed here ... at the All India Institute of Medical Sciences (AIIMS) ...
... eyes could reveal the status of our health and ... disease.// ,Conventional vision tests reveal eyesight abnormalities, such ... Rosen, of Rosen Eye Associates, Manchester, a test of ... heart disease, cancer and diabetes, thanks to its superior ...
... exposure to industrial chemicals is causing a ‘silent pandemic’ ... globe. ,This study was published on Tuesday ... 1-in-6 children and most of the cases are disorders ... that disorders like autism, attention deficit disorder, cerebral palsy ...
... advised to build a three-month stockpile of food, medicine and ... pandemic, a news report said Tuesday. ,An advisory ... in the former British colony urging them to prepare the ... ,It suggests stockpiling 4.5 litres of water per person per ...
... lower the risk of acquiring a sexually transmitted infection, ... ,The November issue of Pediatrics which reports ... of acquiring and spreading such infections by up to ... routine neonatal circumcision. ,This study is only ...
... getting heavier , but a new study by Statistics Canada has a ... pace as they did earlier. //Adults between 18-64 were monitored for ... showed that they have put on weight steadily , but during the ... ,This welcome news is thought to be due to the fact that ...
Cached Medicine News:Health News:Mismanagement of fractures a major concern, say experts 2Health News:Eye could reveal serious health disorder 2Health News:Brain disorders caused by Industrial chemicals 2Health News:Risk of STD Lowered with Circumcision 2
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... Kit Nebulizer Small Volume Medication Mouthpiece 7FT O ... ,These Sidestream® nebulizers are designed to ... any nebulizer treatment with a fast treatment time. ... 7` (84") tubing and a vent seal adapter ...
Nebulizer Adapter Kit 6"...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: